890
Views
4
CrossRef citations to date
0
Altmetric
Review

KDM1 Histone Lysine Demethylases as Targets for Treatments of Oncological and Neurodegenerative Disease

, , , , , & show all
Pages 609-626 | Published online: 25 Jun 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Hermann AM Mucke. (2019) Patent Highlights February–March 2019. Pharmaceutical Patent Analyst 8:4, pages 109-116.
Read now
Paolo Trifirò, Anna Cappa, Silvia Brambillasca, Oronza A Botrugno, Maria Rosaria Cera, Roberto Dal Zuffo, Paola Dessanti, Giuseppe Meroni, Florian Thaler, Manuela Villa, Saverio Minucci, Ciro Mercurio, Mario Varasi & Paola Vianello. (2017) Novel Potent Inhibitors of the Histone Demethylase Kdm1A (Lsd1), Orally Active in a Murine Promyelocitic Leukemia Model. Future Medicinal Chemistry 9:11, pages 1161-1174.
Read now
Alba Maiques-Diaz & Tim CP Somervaille. (2016) LSD1: Biologic Roles and Therapeutic Targeting. Epigenomics 8:8, pages 1103-1116.
Read now
Yi-Chao Zheng, Bin Yu, Zhe-Sheng Chen, Ying Liu & Hong-Min Liu. (2016) TCPs: Privileged Scaffolds for Identifying Potent LSD1 Inhibitors for Cancer Therapy. Epigenomics 8:5, pages 651-666.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.